We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 63

Court of Appeal decides “settled” EPO case law trumps UK precedent on Swiss-type claim to a new dosage regime

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • July 16 2008

The Court of Appeal has decided in the case of Actavis UK Ltd v Merck & Co Inc 2008 EWCA Civ 444, that a Swiss-type claim can be patentable where the novelty is only conferred by a new dosage regime or form of administration of a substance

Paedriatric SPC extension: zero or negative term SPCs

  • Bird & Bird
  • -
  • European Union, United Kingdom
  • -
  • March 11 2009

Zero or negative term SPCs give rise to a unique disunity amongst the granting authorities in the European Member States

Protection of dosage regiment for medicaments under the new European Patent Convention 2000

  • Bird & Bird
  • -
  • European Union
  • -
  • July 16 2008

The discussion before the European Patent Office on patentability of second medical use claims has now entered another round

Edwards Lifesciences AG v Cook Biotech Incorporated

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • July 17 2009

Mr Justice Kitchin handed down a decision only four weeks after the hearing, finding Cook’s patent invalid and not infringed by Edwards’ SAPIEN heart valve

UK Patents Court judgment in Eli Lilly v Human Genome Sciences

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • October 30 2008

The Patents Court (Mr Justice Kitchin) has, somewhat unusually, revoked a patent on the grounds of lack of industrial applicability

Pfizer’s arrangements with Unichem

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • October 30 2007

The High Court dismissed an application for an interim injunction by AAH Pharmaceuticals Limited and seven other pharmaceutical wholesalers to restrain the implementation of Pfizer Limited’s new single “direct to pharmacy” distribution arrangements for its prescription drugs in the UK

Patents Court judgment in Ratiopharm GmbH and Sandoz Limited v Napp Pharmaceutical Holdings Limited

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • March 11 2009

The Patents Court (Mr Justice Floyd) handed judgment down on 16 December 2008 relating to two patents regarding formulations to achieve slow release of the opioid pain killing drug, oxycodone

Does requesting and receiving approval for a pharmaceutical create a threat of patent infringement? A German perspective

  • Bird & Bird
  • -
  • Germany
  • -
  • February 28 2008

Under German law, neither the application for a marketing approval nor obtaining it constitutes a ‘use’ act under Section 9 German Patent Act

New regulatory requirements in the pharmaceutical sector

  • Bird & Bird
  • -
  • European Union
  • -
  • October 30 2008

Regulation (EC) No 19012006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use (hereinafter, “the Paediatric Regulation”) is intended to tackle the problems resulting from the absence of suitably adapted medicinal products for the paediatric population (including inadequate dosage information, non-availability to the paediatric population of therapeutic advances, suitable formulations and routes of administration as well as use of magistral or officinal formulations to treat the paediatric population

Status of the insufficiencyobviousness squeeze - an appraisal of the House of Lords’ Generics et al v Lundbeck judgments

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • May 1 2009

In February 2009 the House of Lords unanimously dismissed an appeal by a number of pharmaceutical companies against the Court of Appeal’s decision to not revoke Lundbeck’s escitalopram patent on grounds of insufficiency